-
2026-06-24
GenSci's Triptorelin Acetate for Injection (II) Secures NMPA Approval for Central Precocious PubertyLearn More
-
2026-06-04
GenSci: Two Innovations Granted IND Clearance by FDALearn More
-
2026-05-28
Dr. Lei Jin of GenSci Shines at J.P. Morgan Global China Summit, Sharing Insights on Innovation and GlobalizationLearn More
-
2026-05-19
GenSci's Innovative IL-1α/β Bispecific Antibody Receives First FDA Clinical ApprovalLearn More
-
2026-05-15
GenSciP166 Selected as Late-Breaking Abstract at SID 2026Learn More
-
2024-07-03
GenSci Invites you to join us in CPHI South East Asia 2024Join us at Booth H23 from July 10 to 12, 2024 to explore GenSci's flagship products.
Learn More
-
2024-06-28
China's First Aqueous Solution Progesterone Injection, Jin Sai Xin® ApprovedA further step towards GenSci's vision of becoming a global leader in Pediatric and Women's Health
Learn More
-
2024-06-19
GenSci and TWi Reach Exclusive Import and Distribution Agreement for Megaxia®Under this agreement, TWi authorizes GenSci Singapore as the sole distributor of Megaxia® in mainland China, Hong Kong, Macau, and Singapore, responsible for the marketing and promotion of this product.
Learn More
-
2024-06-05
Visit GenSci at CPhI China 2024At Booth W4E59, See you there!
Learn More
-
2024-05-26
NMPA Approves Genakumab Injection for Clinical Trial Commencementwhich marks the initiation of bioequivalence studies for the new formulation of Genakumab Injection
Learn More
-
2024-05-17
Jintrolong® PEG-rhGH from GenSci highlighted at ECE 2024Jintrolong® PEG-SOMATROPIN was highlighted during the Growth Hormone Research Society (GRS) symposium at the largest endocrine event in Europe
Learn More